Pete Pharma and FABRX announce strategic partnership
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Element5’s Agentic AI platform will be integrated with the HCHB EHR
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Subscribe To Our Newsletter & Stay Updated